GSK plc (GSK) vs Virax Biolabs Group Limited (VRAX)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| GSK | VRAX | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Biotechnology |
| Size band | LARGE | NANO |
| Listing | NYSE | Nasdaq CM |
| Country | United Kingdom | United Kingdom |
| Theme | pharmaceuticals-large-cap | diagnostics |
| Price and returns | ||
| Last close | $51.10 | $1.19 |
| Return · 1 week | +3.32% | −15.00% |
| Return · 1 month | +2.82% | −48.57% |
| Return · 3 months | −4.86% | −58.82% |
| Return · year to date | +4.74% | +209.90% |
| Return · 1 year | +19.72% | +103.77% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −17.18% | −90.98% |
| 52-week high | $61.70 | $13.19 |
| 52-week low | $42.85 | $0.10 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $101.68B | $1.60M |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $158.70M | $44.74K |
| Employees | 66,841 | 26 |
| Valuation | ||
| Price to earnings · trailing | 15.62× | n/a (negative earnings) |
| Price to earnings · forward | 10.06× | n/a (negative forward earnings) |
| Price to sales | 2.99× | 132.08× |
| Price to book | 4.22× | 0.09× |
| Enterprise value to EBITDA | 10.53× | n/a (negative enterprise value and EBITDA) |
| Enterprise value to revenue | 3.43× | n/a (negative enterprise value) |
| PEG ratio | 6.03 | — |
| Earnings per share · trailing | 3.17 | -12.64 |
| Profitability | ||
| Gross margin | 72.73% | 61.90% |
| Operating margin | 30.94% | −35264.92% |
| Profit margin | 14.52% | — |
| Return on equity | 33.38% | −78.65% |
| Return on assets | 10.01% | −54.23% |
| Growth | ||
| Revenue growth | +5.30% | +684.90% |
| Earnings growth | −69.50% | — |
| Balance sheet and payout | ||
| Debt / equity (%) | 106.50 | 5.65 |
| Current ratio | 0.82 | 9.97 |
| Dividend yield | 3.67% | 0.00% |
| Payout ratio | 56.55% | — |
| Trend and volatility | ||
| RSI · 14 | 61.33 | 37.14 |
| ADX · 14 | 22.21 | 20.33 |
| 50-day average | $49.60 | $2.73 |
| 200-day average | $52.36 | $1.32 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 2.07% | 16.76% |
The full GSK analysis
Everything this table leaves out for GSK plc: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the GSK argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full GSK analysisThe full VRAX analysis
Everything this table leaves out for Virax Biolabs Group Limited: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the VRAX argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full VRAX analysis